All In Biotech

Drug Trial Radar · NCT07298421

A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease

A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Children Aged 2-17 Years With Moderately to Severely Active Crohn's Disease

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Aug 18, 2026

Primary completion

May 31, 2030

Study completion May 30, 2031

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III, double-blind, multi-center treat-through study will evaluate the efficacy and safety of Afimkibart (also known as RO7790121) in children with moderately to severely active Crohn's Disease (CD).

Conditions

  • Moderately to Severely Active Crohns Disease

Interventions

  • AfimkibartDrug

    Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Clinical Remission per Pediatric Crohn's Disease Activity Index (PCDAI)Time frame: At Week 52
  2. Percentage of Participants With Endoscopic ResponseTime frame: At Week 52

Locations

19 sites in 8 countries. Site status is shown where the registry gives one.

  • NYU Langone Health

    New York, New York · Recruiting

  • Texas Digestive Specialists

    Harlingen, Texas · Recruiting

  • Mater Hospital Brisbane

    South Brisbane, Queensland, Australia · Recruiting

  • Royal Children's Hospital

    Parkville, Victoria, Australia · Recruiting

  • Perth Children's Hospital

    Nedlands, Western Australia, Australia · Recruiting

  • Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • CECIP - Centro de Estudos Clínicos do Interior Paulista

    Jaú, São Paulo, Brazil · Recruiting

  • BR Trials - Pesquisa Clínica

    São Paulo, São Paulo, Brazil · Recruiting

  • FAICIC Clinical Research

    Veracruz, Mexico · Recruiting

  • Centro de Investigación Clínica Acelerada, S.C

    Mexico City, Mexico CITY (federal District), Mexico · Recruiting

  • IATROS International

    Bloemfontein, South Africa · Recruiting

  • Emmed Research

    Pretoria, Gauteng, South Africa · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

  • Chulalongkorn University

    Bangkok, Thailand · Recruiting

  • Siriraj Hospital

    Bangkok, Thailand · Recruiting

  • Ramathibodi Hospital

    Bangkok, Thailand · Recruiting

  • Birmingham Children's Hospital

    Birmingham, United Kingdom · Recruiting

  • King's College Hospital

    London, United Kingdom · Recruiting

  • Sheffield Childrens Hospital

    Sheffield, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.